spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Isis Pharmaceuticals 

 HSMN NewsFeed - 11 Oct 2017
SutroVax Appoints Veteran Vaccine Experts to Executive Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jan 2016
Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 5 Jan 2016
Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 6 Jan 2015
Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jun 2014
Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2014
Regulus Appoints Head of Regulus microMarkers(TM) R&D Division
Biopharmaceuticlas Personnel
 HSMN NewsFeed - 4 Feb 2014
Regulus Strengthens Executive Management Team with Addition of David Szekeres as Chief Business Officer and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Sep 2013
Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 14 Aug 2013
SAGE Therapeutics Appoints Biotech Industry Veteran Dr. Jeffrey Jonas to Chief Executive Officer; Expands Leadership Team with Two Key Appointments
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 18 Dec 2012
AtheroNova Names New Chief Medical Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 27 Nov 2012
Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2012
Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 1 Aug 2012
Lpath Appoints Daniel L. Kisner, M.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jul 2012
NovImmune Strengthens Board and Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2012
Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Myotonic Dystrophy
Biopharmaceuticals
 HSMN NewsFeed - 6 Mar 2012
Tekmira Files Motion to Dismiss in Patent Infringement Suit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 2 Dec 2011
Pfizer Completes Acquisition of Excaliard
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Nov 2011
Pfizer to Acquire Excaliard Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jul 2011
Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro(R))
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 May 2011
Regulus Therapeutics Expands Executive Team with Recent Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2011
Regulus Therapeutics Appoints Lars Karlsson, M.D., Ph.D., VP of Immunology and Fibrosis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Mar 2011
Stellar Biotechnologies Appoints Vice President, Business Development & Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2011
Aegerion Pharmaceuticals Appoints Diane L. Tribble, Ph.D., M.M.Sc., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Regulus Therapeutics Promotes Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2010
Regulus Therapeutics Strengthens Immunology Leadership Team with New Key Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2010
Sanofi-Aventis Completes $10 Million Equity Investment in Regulus Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2010
AVI BioPharma Announces Key Leadership Appointments to Advance Capabilities in Drug Discovery, Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2010
Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2010
Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2009
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Nov 2009
Altair Therapeutics Secures $17 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 May 2009
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2009
Altair Therapeutics Appoints Dr. Joel Martin President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 May 2009
Archemix Appoints Ken Bate as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2009
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jan 2009
Archemix Announces Continued Progress with Business Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jan 2009
Alnylam Provides Update on Kreutzer-Limmer Patent Family
Biopharmaceuticals
 HSMN NewsFeed - 3 Dec 2008
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Oct 2008
Pervasis Therapeutics Appoints Life Sciences Industry Executive Frederic Chereau as Company's President and Chief Executive Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 3 Sep 2008
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2008
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jul 2008
Isis Announces Appointment of Martin P. Bedigian, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2008
Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences
Biopharmaceuticals
 HSMN NewsFeed - 24 Jun 2008
Genzyme and Isis Complete Licensing of Mipomersen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 25 Apr 2008
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2008
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2008
Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
Biopharmaceuticals Diagnostics Acquisitions
 HSMN NewsFeed - 7 Jan 2008
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 18 Dec 2007
Forward Ventures Joins Series A Syndicate for Newly Formed Altair Therapeutics
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Dec 2007
Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2007
Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Nov 2007
Alnylam Expands Management Team with New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2007
Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 2 Oct 2007
Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 2 Oct 2007
Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 27 Sep 2007
Isis Acquires Symphony GenIsis
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Jun 2007
Nventa hires Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2007
Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2007
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 22 Jan 2007
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
Biopharmaceuticals Endocrinology Ophthalmology FDA
 HSMN NewsFeed - 22 Jan 2007
Isis Announces Appointment of Jeffrey M. Jonas, M.D. as Executive Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2007
Kosan Appoints Jane Green as Vice President, Corporate Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2006
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 20 Sep 2006
Kalypsys Appoints 2 Executives to Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2006
Isis Pharmaceuticals Receives Orphan Drug Status for ISIS 301012 for the Treatment of Homozygous Familial Hypercholesterolemia
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 56

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 56 additional stories matching:
Isis Pharmaceuticals
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.